PAH News

Pulnovo Medical recently raised an undisclosed amount totaling millions of dollars in investment funding to support clinical trials and product development related to pulmonary arterial hypertension (PAH). “The road of global medical innovation has never been an easy journey,” Cynthia Chen, Pulnovo’s executive president, said in a…

PulmoSIM Therapeutics has joined with scientists at National Jewish Health hospital and Brown University to advance PT001, its investigational and potentially disease-modifying therapy for pulmonary arterial hypertension (PAH), into clinical trials. The partnership follows PT001 being designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status…

A protein called TIFA is elevated in the blood cells of people with pulmonary arterial hypertension (PAH), suggesting this protein is involved in the biological processes that drive the disease, according to a new study. The findings were published in the journal Scientific Reports, in the study, “…

An investigational therapy called R-107 completely stopped the progression of pulmonary arterial hypertension (PAH) in a rat model and may become the first medicine to reverse the increasing blood pressure characteristic of the disease, a study suggested. Now, R-107’s developer, Claritas Pharmaceuticals, plans to begin clinical testing…

In people experiencing a pulmonary embolism, higher-than-normal arterial stiffness at the time of hospital discharge increased the risk of pulmonary arterial hypertension (PAH) when evaluated one month later, according to a study in Italy. Given that this patient population is at risk of chronic thromboembolic pulmonary hypertension…

An upcoming series of educational virtual events for people with pulmonary arterial hypertension (PAH) and their caregivers will offer insights and perspectives about how to manage life with PAH. The National Broadcast Series will include three talks from August to October. Each of the one-hour talks is scheduled to…

TPN171H, an experimental oral therapy for pulmonary arterial hypertension (PAH), was generally safe and showed a favorable pharmacological profile in healthy volunteers, according to data from a Phase 1 clinical trial. The therapy — previously reported to be a more potent and selective PDE5 suppressor than sildenafil in…

A protein known as cell division cycle protein 2 (CDC2) enhances the proliferation of pulmonary artery smooth muscle cells — those lining the walls of lung arteries — in people with pulmonary arterial hypertension (PAH), a study reported. Additionally, the increased level of CDC2 in these cells was found…

The PAPi blood pressure test was able to accurately predict mortality in Asian people with pulmonary arterial hypertension (PAH), a 14-year study revealed. Despite that finding, the multi-factor REVEAL score was found to still be the best predictor for mortality risk in PAH. “In our analysis, low PAPi was…

People with stable pulmonary arterial hypertension (PAH) can safely switch from Tracleer (bosentan) to Letairis (ambrisentan) without compromising their heart function or general health status, a study from China reports. PAH patients in Hunan province may also benefit financially by moving from Tracleer to Letairis, as it…

A study of rare gene variants has identified two new candidates — fibulin 2 (FBLN2) and platelet-derived growth factor D (PDGFD) — that increase risk for adult-onset idiopathic pulmonary arterial hypertension (IPAH). In-depth genetic analyses also predicted that about 15% of IPAH cases in children are caused by de…

Dosing has begun in a clinical trial testing AER-901, Aerami Therapeutics‘ inhaled formulation of imatinib, which is being investigated as a potential treatment for pulmonary arterial hypertension (PAH). “We are pleased to announce that the dosing of subjects in our Phase 1 trial is ongoing and that we expect to…